Abstract
The purpose of this study was to determine the minimum effective protective dose of PGE 2 given concurrently with ASA. Thirty-two adult male volunteers completed a double-blind placebo-controlled experiment. Fecal blood loss was measured by the 51 Cr technique for 15 days. ASA (650 mg four times daily) was given for the middle 5 days and in addition subjects received PGE 2 orally in doses of 0.04 mg, 0.25 mg or 0.5 mg or placebo four times daily. In the control group ASA caused a significant increase in fecal blood and this was reduced in a dose-dependent manner by the three doses of PGE 2 employed. Serum salicylate was elevated similarly in all four groups. Four subjects receiving 0.5 mg PGE 2 experienced mild transient side effects. It is concluded that concurrent treatment with oral PGE 2 affords significant dose-dependent protection against ASA-induced gastrointestinal blood loss and that even a dose of 0.04 mg four times daily provided some protection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
